

## AMENDMENT TO THE CLAIMS

Claims 1-19 (Cancelled)

20. (Currently Amended) An isolated nucleic acid ~~of at least 12 contiguous nucleotides in length~~ selected from the group consisting of (a) a nucleic acid of at least 12 contiguous nucleotides consisting of SEQ ID NO:1; (b) a nucleic acid of at least 12 contiguous nucleotides consisting of SEQ ID NO:4; (c) a nucleic acid of at least 12 contiguous nucleotides complementary to SEQ ID NO:1, and (d) a nucleic acid of at least 12 contiguous nucleotides complementary to SEQ ID NO:4 wherein said isolated nucleic acid of (a) or (b), ~~(c) or (d)~~ is capable of specifically binding to the complement of the polynucleotide of SEQ ID NO:1 or SEQ ID NO:4; ~~the complement of the polynucleotide of SEQ ID NO:4; SEQ ID NO:1; or SEQ ID NO:4, respectively; and the nucleic acid of (c) or (d) is capable of specifically binding to the polynucleotide of SEQ ID NO:1 or SEQ ID NO:4, respectively.~~

21. (Previously Presented) The nucleic acid of claim 20 which is 12 to about 75 contiguous nucleotides in length.

22. (Previously Presented) The nucleic acid of claim 20 which is 12 to 14 nucleotides in length.

23. (Previously Presented) The nucleic acid of claim 20 which is 14 to 18 nucleotides in length.

24. (Previously Presented) The nucleic acid of claim 20 which is 18 to 20 nucleotides in length.

25. (Previously Presented) The nucleic acid of claim 20 which is 20 to about 75 nucleotides in length.

26. (Previously Presented) The nucleic acid of claim 20 labeled with a radioactive, fluorescent, enzymatic, or chromogenic marker.

27. (Previously Presented) The nucleic acid of claim 20 wherein the nucleic acid is DNA.

28. (Previously Presented) The nucleic acid of claim 27 selected from the group consisting of (a) a nucleic acid consisting of SEQ ID NO:9; (b) a nucleic acid consisting of SEQ ID NO:10; (c) a nucleic acid consisting of SEQ ID NO:11; (d) a

nucleic acid complementary to SEQ ID NO:9; (e) a nucleic acid complementary to SEQ ID NO:10; and (f) a nucleic acid complementary to SEQ ID NO:11.

29. (Previously Presented) The nucleic acid of claim 27 selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.

30. (Previously Presented) A composition comprising the nucleic acid of claim 20 and a diluent or carrier.

Claims 31-33(Cancelled)

34. (Previously Presented) The nucleic acid of claim 20 wherein the nucleic acid is DNA, or RNA.

35. (Previously Presented) The nucleic acid of claim 20 where the nucleic is RNA.

Claims 36-40(Cancelled)

41. (Currently Amended) An oligonucleotide of at least 14 nucleotides in length capable of hybridizing, under conditions of moderate stringency, to specifically forming a stable duplex with a nucleic acid which encodes a polypeptide comprising SEQ ID NO:3 or SEQ ID NO:6.

42. (Previously Presented) The oligonucleotide of claim 41 which is DNA or RNA.

43. (Previously Presented) The oligonucleotide of claim 41 which is DNA.

44. (Previously Presented) The oligonucleotide of claim 41 which is RNA.

45. (Previously Presented) A composition comprising the oligonucleotide of claim 41 and a pharmaceutically acceptable diluent or carrier.